In the propensity score–matched population, we observed a 0.89-fold risk of gout in patients receiving SGLT2 inhibitors compared with DPP4 inhibitors using both univariate (HR, 0.89; 95% CI, 0.82-0.97; P = .005) and multiple Cox proportional hazards regression (HR, 0.89; 95% CI, 0.82-0.96; P = .004) models (Table). The gene discussed is DPP4; the disease is gout.